IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re the application of: Freeman, Gordon J. et al.

AUG U 8 2001 c

rial No.: 09/425,516

Filed: October 22, 1999

For: Novel CTLA4/CD28 Ligands And Uses Therefor

Attorney Docket No.: RPI-004C3CN

Group Art Unit: 1644

Examiner: Gambel, P.

RECEIVED

AUG 1 0 2001

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

Bv:

Megan E. Wiliams, Esq. Registration No. 43,270

Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 C.F.R. §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a Continuation Application of U.S. Serial No. 08/479,744, filed June 7, 1995 (Atty. Docket No. RPI-004CP3), which is a Continuation-in-Part of U.S. Serial No. 08/280,757, filed July 26, 1994 (Atty Docket No. RPI-004C2CPA), which is a Continuation-in-Part of U.S. Serial No. 08/109,393, filed August 19, 1993 (Atty. Docket No. RPI-004CP), which is a Continuation-in-Part of U.S. Serial No. 08/101,624, filed July 26, 1993 (Atty. Docket No. RPI-004). U.S.

Serial No. 08/479,744 is also a Continuation-in-Part of U.S. Serial No. 08/147,773, filed November 3, 1993 (Atty. Docket No. RPI-008). Copies of the references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior applications, and, in accordance with 37 C.F.R. §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request. However, certain references (A4, A5, A8, A9, A15, B15, C1, D1-D6 and D13-D19) have not been previously cited, and are therefore enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 C.F.R. § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted, LAHIVE & COCKFIELD, LLP

Megan E. Williams, Esq. Registration No. 43,270 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: August 6, 2001

AEM/MEW/JKR/alf